News
25 Jahre ROTOP: Ein Jubiläum mit Blick nach vorn
21. November 2025 - ROTOP Pharmaka feiert 25 Jahre und startet zugleich die größte Wachstumsinitiative der Unternehmensgeschichte: Mit einem zweistelligen Millioneninvestment baut ROTOP die Produktions und Entwicklungskapazitäten in Dresden Rossendorf deutlich aus. Geplant sind zwei neue, hochautomatisierte Fabriken für diagnostische und therapeutische Radiopharmaka, die ab 2028 schrittweise in Betrieb gehen.
ROTOP featured in VentureCapital Magazine
15. August 2025 - We are delighted to be featured in the latest issue of VentureCapital Magazine, which spotlights the Dresden region as a high-performance hub for key players and innovators in radiopharmaceutical innovation. ROTOP Pharmaka is recognized as a leading manufacturer of radiopharmaceuticals, including an iodine-123 compound used in Parkinson’s diagnostics.
New Milestone: RoTecPSMA® Approved in Switzerland
12. August 2025 - RoTecPSMA® Approved in Switzerland – Expanding Access to Advanced Prostate Cancer Diagnostics. We are delighted to announce that RoTecPSMA® has received marketing authorization in Switzerland, marking another important milestone in the European rollout of this innovative diagnostic solution. This approval, achieved in close collaboration with our trusted partner and marketing authorization holder medeo AG, paves the way for Swiss patients to benefit from our PSMA SPECT tracer.
Team ROTOP is back from SNMMI 2025 in New Orleans
18. Juli 2025 - Team ROTOP is back from SNMMI 2025 in New Orleans and feels energized by the global momentum in radiopharmaceuticals. Team ROTOP - Jens Junker, Felix Roschke, Thomas Gottlieb and Tanmaya Joshi - just returned from SNMMI 2025 in New Orleans. This year, the event brought together nearly 8,000 professionals from across the nuclear medicine and radiopharmaceutical world.
First marketing authorization for RoTecPSMA®
16. April 2025 - First marketing authorization for RoTecPSMA®. We are thrilled to announce that RoTecPSMA® has been approved in the United Kingdom! RoTecPSMA® is a technetium-99m cold kit for SPECT imaging of prostate cancer patients and the first PSMA-SPECT tracer approved in a European country. It marks a significant step forward in closing a gap in patient care, making advanced diagnostics more accessible for those affected by prostate cancer.
ROTOP Pharmaka GmbH Announces Investments from GENUI & SHS Capital and New President, ROTOP USA.
20. Januar 2025 - ROTOP Pharmaka GmbH is pleased to announce new investments secured from GENUI & SHS Capital along with the appointment of Andrew Varghese as its new President of ROTOP USA.
